drugset / Trial / NCT07664553

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

NCT07664553

Phase 3 Not yet recruiting 600 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)

Timeline

Start
2026-07-06
Primary completion
2028-05-23
Completion
2028-05-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Elecoglipron Unknown Oral